<DOC>
	<DOCNO>NCT02229383</DOCNO>
	<brief_summary>Study D5553C00002 multicenter , randomize , double-blind , placebo-controlled , parallel group , Phase 3 study compare safety efficacy exenatide weekly ( EQW ) add titrate basal insulin glargine without metformin placebo add titrate basal insulin glargine without metformin patient type 2 diabetes mellitus ( T2DM ) . Eligible patient randomize Visit 5 ( Day 1 ) receive either EQW add titrate basal insulin glargine , without metformin ≥1500 mg/day , placebo add titrate basal insulin glargine , without metformin ≥1500 mg/day , 28-week treatment period .</brief_summary>
	<brief_title>Phase III Study Evaluate Safety Efficacy Added Exenatide Versus Placebo Titrated Basal Insulin Glargine Inadequately Controlled Patients With Type II Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Has diagnosis Type 2 Diabetes Mellitus ( T2DM ) Has HbA1c 7.5 % 12.0 % , inclusive , Visit 1 ( Screening ) . Has fast plasma glucose ( FPG ) concentration &lt; 280 mg/dL ( 15.6 mmol/L ) Visit 1 ( Screening ) Treated basal insulin glargine dose ≥20 units/day daily least 6 week prior Screening , combination diet exercise alone combination : 1. stable dose metformin ( ≥1500 mg/day ) least 8 week prior Visit 1 2. stable dose metformin ( ≥1500 mg/day ) least 8 week prior Visit 1 ( Screening ) stable dose sulfonylurea least 8 week prior Screening visit Exclusion criterion : Serum calcitonin concentration ≥40 pg/mL ( ≥40 ng/L ) Visit 1 ( Screening ) History , currently , acute chronic pancreatitis , triglyceride concentration ≥500 mg/dL ( ≥5.65 mmol/L ) Visit 1 Positive serological test hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Diabetes drug</keyword>
	<keyword>Treatment efficacy</keyword>
	<keyword>Placebo</keyword>
	<keyword>Metabolism</keyword>
	<keyword>Cardiovascilar metabolic</keyword>
</DOC>